ArticleFunctional & integrative genomics2026
LncRNA TUG1 promotes hepatic lipid accumulation by targeting the miR-29a-3p/SREBP-2/HMGCR axis in MAFLD.
Article in Functional & integrative genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Agmatine protects against MAFLD via decreasing RBM15/IGF2BP2-mediated mMolecular biology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic-associated fatty liver disease (MAFLD) is a globally prevalent liver disorder, and long non-coding RNAs (lncRNAs) play a crucial role in its pathogenesis. However, the specific function of taurine up-regulated gene 1 (TUG1) remains incompletely understood. This study examined the molecular interactions among TUG1, miR-29a-3p, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and sterol regulatory element-binding protein 2 (SREBP-2). Two MAFLD mouse models were established, and liver damage and lipid accumulation were assessed using hematoxylin and eosin (HE) and Oil Red O staining. The expression levels of these factors were measured in liver tissues, and TUG1 expression was knocked down to evaluate its functional impact. The results indicate that TUG1 could bind to miR-29a-3p, thereby regulating the expression of HMGCR and SREBP-2. Tug1 expression is upregulated in livers of MAFLD models compared with control groups, showing a negative correlation with miR-29a-3p and a positive correlation with HMGCR and SREBP-2. Furthermore, the knockdown of Tug1 in mouse livers reduced hepatic lipid deposition significantly. In summary, TUG1 could modulate the SREBP-2/HMGCR pathway by binding to miR-29a-3p, thus influencing lipid metabolism. These findings suggest that TUG1 may serve as a potential therapeutic target for MAFLD.
Indexed as
Identifiers
41609940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.